Literature DB >> 35059119

Novel Macrocyclic LRRK2 Inhibitors for Treating Parkinson's Disease.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35059119      PMCID： PMC8762723          DOI： 10.1021/acsmedchemlett.1c00687

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  LRRK2 at the pre-synaptic site: A 16-years perspective.

Authors:  Francesca Pischedda; Giovanni Piccoli
Journal:  J Neurochem       Date:  2021-02-05       Impact factor: 5.372

Review 2.  The Cell Biology of LRRK2 in Parkinson's Disease.

Authors:  Ahsan Usmani; Farbod Shavarebi; Annie Hiniker
Journal:  Mol Cell Biol       Date:  2021-04-22       Impact factor: 4.272

Review 3.  New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.

Authors:  Konstantin Senkevich; Uladzislau Rudakou; Ziv Gan-Or
Journal:  Neuropharmacology       Date:  2021-10-07       Impact factor: 5.250

Review 4.  Molecular chaperones and Parkinson's disease.

Authors:  Shenglan Hu; Jieqiong Tan; Lixia Qin; Lingling Lv; Weiqian Yan; Hainan Zhang; BeiSha Tang; Chunyu Wang
Journal:  Neurobiol Dis       Date:  2021-10-07       Impact factor: 5.996

Review 5.  The multi-faceted role of mitochondria in the pathology of Parkinson's disease.

Authors:  Dennison Trinh; Ahmad R Israwi; Lindsay R Arathoon; Jacqueline A Gleave; Joanne E Nash
Journal:  J Neurochem       Date:  2020-09-20       Impact factor: 5.372
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.